CareDx, Inc 10-Qquarter ended 2026-03-31

Executive Summary

CareDx earns revenue from transplant testing, laboratory products, pharmacy services and digital tools sold to transplant centers, clinicians and patients. It is investing in clinical evidence and new testing services, while signed post-quarter transactions would sell its laboratory-products business and add Naveris. Q1 growth accelerated and CareDx returned to profitability, but collections on older tests—not just increased testing—were critical to the result. The opportunity is wider adoption of transplant monitoring; the main threat is uncertain reimbursement, and management still expects net losses over the next several years.

What's Happening in the Business

Transplant testing drove the quarter. AlloSure and AlloMap serve kidney, heart and lung transplant monitoring, and CareDx is funding clinical and economic studies to support adoption and payer coverage. Testing volume increased 17% to ≈54,900 tests, but revenue grew much faster because collections improved on previously performed tests. The gap matters: reported growth overstates the increase in current testing activity.

Patient and digital solutions benefited from pharmacy sales and an expanded Ottr customer base. However, pharmacy costs rose faster than that business’s revenue, limiting its contribution to gross profit.

After quarter-end, CareDx signed two portfolio-changing agreements: on 4/15/2026, it agreed to sell CareDx AB and related kitted laboratory products and software to Eurobio Scientific for $170M cash; on 4/28/2026, it agreed to acquire Naveris for $160M cash plus up to $100M tied to FY2026–FY2027 revenue milestones. Both remain subject to adjustments. The sale would broadly fund the acquisition’s upfront price, but contingent payments create additional exposure.

The board also authorized a new $100M repurchase program beginning 4/30/2026. This is discretionary, not completed spending, and competes with acquisition payments and operating investment.

Key Financial Highlights

Q1 2026 versus Q1 2025:

• Revenue quality: $17.7M came from increased net collections on prior-period tests, partly offset by a $3.4M payer-refund reserve adjustment; the resulting net benefit exceeded operating profit. The comparable quarter included a $1.1M reduction related to prior-period tests.
• Cost drivers: Sales and marketing rose 32% to $30.4M, general and administrative expense rose 34% to $30.5M, and R&D rose 16% to $21.4M. Settlement expense fell to $0.600M from $5.36M, so part of the profit improvement reflects a lower legal charge.
• Business economics: Patient and digital solutions costs rose 52% to $11.7M, mainly from pharmacy purchases; products declined because of weaker next-generation sequencing kit sales.
• Cash and dilution: Operating cash flow was $4.33M versus $(26.6)M, supported by $9.8M of noncash stock-based compensation despite compensation payouts. Capital expenditures left FCF of $0.514M. Cash, cash equivalents and marketable securities totaled $198M, with no debt; no shares were repurchased, and quarter-end shares increased 0.7% during Q1.

Risk Assessment

• Reimbursement and collections: The growing payer-refund reserve, a significant Medicare Advantage payer dispute and proposed Medicare coverage restrictions could reverse collections or limit payment for AlloSure and other tests.
• Profit durability and capital allocation: Management expects continuing losses, while the acquisition, potential milestone payments and buyback authorization could consume liquidity faster than the quarter’s limited FCF replenishes it.
• Patent litigation: Natera’s appeal could restore exposure of up to $96.3M plus interest despite the earlier reversal of its patent award.
• Laboratory concentration: All U.S. testing runs through one Brisbane, California laboratory without a redundant U.S. facility or earthquake insurance, making disruption potentially severe.
• Adoption and competition: Entrenched biopsy protocols and competing molecular tests could constrain adoption or pricing unless CareDx’s studies demonstrate clinical and economic value.

What to Watch

• Transplant testing demand: Volume grew 17%; sustained growth in AlloSure and AlloMap testing would support adoption, while slowing volume would expose reliance on collections from older tests.
• Reimbursement durability: Watch whether prior-period collections persist without further refund-reserve increases; adverse payer decisions or tighter Medicare criteria would weaken revenue quality.
• Portfolio execution: The Eurobio sale and Naveris acquisition are signed, not completed; subsequent filings should show closing, Naveris revenue and integration progress, or delays and impairment.
• Sustainable profitability: Operating profit remains thin and management expects losses; repeat profits and positive FCF without large collection catch-ups would strengthen the case, while renewed cash burn would weaken it.